LY3841136 Monotherapy and Tirzepatide Combination Safety Assessed in Japanese Obesity Study

The global prevalence of obesity and overweight continues to rise, posing significant public health challenges due to associated comorbidities like type 2 diabetes, cardiovascular disease, and metabolic dysfunction-associated steatotic liver disease (MASLD). While current pharmacotherapies, including GLP-1 receptor agonists, have shown efficacy, many patients still struggle to achieve optimal weight loss or experience side effects. Combination therapies targeting multiple pathways offer a promising strategy to enhance efficacy and improve tolerability. Investigating novel compounds like LY3841136, especially in combination with established agents like tirzepatide (a dual GLP-1/GIP receptor agonist), could lead to more effective and personalized treatment options, particularly for specific ethnic populations like Japanese individuals who may exhibit different metabolic responses.

This Phase 1, randomized, double-blind, multiple-ascending dose study enrolled 128 Japanese participants with obesity or overweight. The study was divided into two parts: Part A evaluated LY3841136 monotherapy, administered subcutaneously (SC), against a placebo. Part B assessed LY3841136 in combination with tirzepatide (SC), as well as each drug alone with its respective placebo, and a dual placebo arm. The primary endpoint for Part A was the number of participants experiencing one or more serious adverse events (SAE) considered related to the study drug. The study also aimed to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of the interventions.

While this study is marked as completed, specific pharmacokinetic, pharmacodynamic, or safety outcomes, including the incidence and nature of serious adverse events (SAEs), have not yet been publicly disclosed or published. The primary objective was to assess the safety and tolerability profile of LY3841136 as a monotherapy and when co-administered with tirzepatide. The study design focused on identifying any dose-limiting toxicities or unexpected adverse reactions across multiple ascending doses in the Japanese participant cohort. Further details regarding drug exposure, systemic clearance, half-life, and any observed effects on metabolic markers are anticipated upon the full publication of the study results. Without specific data points, no quantitative findings on efficacy or adverse event rates can be reported at this time.